The public issue is entirely an offer-for-sale (OFS) of up to 21.7 million shares by the promoters and other shareholders to the tune of around ₹1,800 crore, said bankers. The company operates under the “Blue Jet” brand offering niche products targeted at innovator pharmaceutical companies and multinational generic pharmaceutical companies.
Mcap of top-10 most valued firms slumps Rs 4.95 lakh cr; TCS, Reliance hardest hit
The combined market valuation of all the top-10 most valued firms plunged Rs 4,95,061 crore last week, in line with a bearish trend in equities,
December 22, 2024